347 related articles for article (PubMed ID: 18490163)
1. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Dixon JM
Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
[TBL] [Abstract][Full Text] [Related]
2. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
3. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
4. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
5. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
6. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
7. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
Del Mastro L; Clavarezza M; Venturini M
Cancer Treat Rev; 2007 Dec; 33(8):681-7. PubMed ID: 17850976
[TBL] [Abstract][Full Text] [Related]
8. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
Toi M; Yamashiro H; Tsuji W
Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
[TBL] [Abstract][Full Text] [Related]
9. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
Gligorov J; Pritchard K; Goss P
Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
[TBL] [Abstract][Full Text] [Related]
11. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Poole R; Paridaens R
Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
[TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
Ingle JN
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
[TBL] [Abstract][Full Text] [Related]
13. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
Mamounas EP
Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
[TBL] [Abstract][Full Text] [Related]
14. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
Spicer J; Ellis P
Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
[TBL] [Abstract][Full Text] [Related]
15. Early recurrence risk: aromatase inhibitors versus tamoxifen.
Bria E; Carlini P; Cuppone F; Vaccaro V; Milella M; Cognetti F
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1239-53. PubMed ID: 20735310
[TBL] [Abstract][Full Text] [Related]
16. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
17. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D; Williamson D
Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
[TBL] [Abstract][Full Text] [Related]
18. Clinical practice decisions in endocrine therapy.
Untch M; Thomssen C
Cancer Invest; 2010; 28 Suppl 1():4-13. PubMed ID: 20653403
[TBL] [Abstract][Full Text] [Related]
19. A review of the BIG results: the Breast International Group 1-98 trial analyses.
Doughty JC
Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
[TBL] [Abstract][Full Text] [Related]
20. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]